Trial NCT04285268

View at ClinicalTrials.gov 
Org. Study IDs: 011915
Secondary IDs: 011915 NCI-2020-00904 P30CA072720

Last trial update was posted on 2020-06-16

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Bortezomib Immunoglobulins Rituximab Venetoclax

MeSH Conditions

Burkitt Lymphoma Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Recurrence

Other Conditions

High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Stopping Reasons

funding available

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID